The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal’s Zegfrovy (sunvozertinib) to treat a ...

Early commercialisation is one of the most demanding stages in bringing a therapy to market, and the challenges are only ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).

A WHO report emphasises the serious global impact of antimicrobial resistance, which exacerbates the substantial burden of ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

Camera fatigue: being on camera means always being on show. This can be distracting for some individuals who are constantly ...

The European Commission (EC) has granted conditional approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab) to treat a ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

The Communiqué Awards returned for its 27th year on 3 July to celebrate excellence in healthcare communications and showcase ...